Can-Fite's New Milestone in Obesity Treatment
Namodenoson is an oral drug with a proven favorable safety profile
In a significant development for obesity treatments, Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) has received a patent allowance for its lead drug candidate Namodenoson in Australia. This decision marks a notable advancement in the company's ongoing efforts to tackle metabolic diseases, particularly Metabolic Dysfunction-associated Steatohepatitis (MASH) and obesity.
Understanding Namodenoson and its Potential
Namodenoson is designed to facilitate fat loss through its interaction with the A3 adenosine receptor (A3AR). This small, orally bioavailable drug has demonstrated an impressive safety profile across various clinical studies, positioning it as a promising option for patients battling obesity.
Patented Formulation and Global Reach
The granted patent, numbered 2020205042, specifically covers methods for treating obese individuals by administering Namodenoson. With the patent in place until 2040, it solidifies Can-Fite’s intellectual property rights in Australia, adding to its existing portfolio of approved patents worldwide, including in regions like Europe and the United States.
Scientific Evidence and Efficacy
Research supporting Namodenoson's effectiveness highlights its ability to lower fat levels in cells, attributed to an increase in the hormone adiponectin, which regulates fat production. Experimental studies have shown that Namodenoson notably reduced body weight in animal models induced to be obese by a high-fat diet. In human trials, particularly a Phase IIa study, MASH patients experienced an average weight reduction of 2.3% after three months, alongside elevated serum adiponectin levels, indicating its potential benefit for obese patients.
Expert Insights on the Development
Dr. Pnina Fishman, Can-Fite's Chief Scientific Officer and Chairperson, expressed her excitement regarding the patent approval. "We are delighted that the product protection of Namodenoson in the area of obesity has been accepted in Australia and will be valid till 2040. Namodenoson is currently in a Phase IIb study for MASH, where most patients are obese. We are eager to observe its anti-obesity effects in this clinical study,” she stated.
The Market Potential for Obesity Treatments
The global market for obesity treatments is expansive, driven by increasing awareness of the disease’s link to chronic health conditions. Recent market research indicates that the obesity treatment market was valued at approximately USD 12 billion, emphasizing the lucrative opportunity for effective therapeutic solutions.
About the Drug and the Company
Namodenoson’s potential is being further explored through various clinical trials, including ongoing evaluations in pivotal Phase III trials targeting advanced liver cancer and Phase II trials for steatotic liver disease as well as pancreatic cancer. Its selective action on A3AR, which is prominently expressed in diseased cells, contributes to its favorable safety profile, making it an attractive candidate among current therapies.
Can-Fite BioPharma’s Broader Mission
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) aims to harness its innovative platform to address significant medical needs in oncology and inflammatory diseases. The company's lead therapeutic, Piclidenoson, has also shown promise, with recent reports from a Phase III trial for psoriasis suggesting positive outcomes. The strategic direction includes evaluating Namodenoson in multiple clinical settings, reaffirming its commitment to enhancing patient health outcomes across several disease states.
Frequently Asked Questions
What is Namodenoson used for?
Namodenoson is primarily being developed as a treatment for obesity, metabolic dysfunction-associated steatohepatitis (MASH), and various forms of cancer.
What are the key benefits of the new patent?
The new patent for Namodenoson provides exclusive rights to Can-Fite for its anti-obesity use in Australia until 2040, enhancing its market position and potential revenue opportunities.
How does Namodenoson work?
Namodenoson acts on the A3 adenosine receptor, helping to regulate fat production and decreasing fat cell levels, while promoting weight loss in clinical settings.
What studies is Can-Fite conducting with Namodenoson?
Can-Fite is currently conducting Phase IIb trials for MASH and planning further studies in pancreatic cancer, as well as evaluating its effects in advanced liver cancer.
How significant is the obesity treatment market?
The obesity treatment market is substantial, valued at around USD 12 billion, reflecting growing healthcare investments in addressing obesity-related health issues.
